All In MedTech

FDA Clearance Tracker · P250017

GORE® VIABAHN® FORTEGRA Venous Stent

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Dec 19, 2025

Approved

Time to decision

182 days

Received Jun 20, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250017
Device name
GORE® VIABAHN® FORTEGRA Venous Stent
Applicant location
Flagstaff, AZ
Received
Jun 20, 2025
Decided
Dec 19, 2025
Decision
Approved
Supplements
3 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QTL

FDA's approval statement

As written in FDA's record.

The GORE® VIABAHN® FORTEGRA Venous Stent is indicated for use in the treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QTL (Stent, vena cava).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for W. L. Gore & Associates, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.